Robert J Chao

US Patent:

6414536, Jul 2, 2002

Filed:

Aug 4, 2000

Appl. No.:

09/632407

Inventors:

Robert L. Chao - Los Altos CA 94022

International Classification:

H03K 1772

US Classification:

327540, 327563

Abstract:

An improved voltage reference circuit relies on electrically adjustable analog devices fabricated on a common substrate. The circuit has two electrically adjustable matched transistor pairs. A first matched transistor pair includes an adjusting transistor and a differential pair transistor. A second matched transistor pair also includes an adjusting transistor and a differential pair transistor. Each of the matched transistor pairs share an insulated gate or electrically connected insulated gates. Geometrical and electrical matching occurs as between the two adjusting transistors and between the two differential pair transistors. The two differential pair transistors are electrically connected at the source terminals to form a differential circuit. A feedback loop, which includes an amplifier, a fixed resistor and a current source complete the circuit.

US Patent:

7524880, Apr 28, 2009

Filed:

Jun 9, 2005

Appl. No.:

11/148728

Inventors:

Li Li - Sunnyvale CA, US
Robert Chao - Santa Clara CA, US
Adam Hughes - Belmont CA, US
Yu-Hua Ji - Redwood City CA, US
Davar Khossravi - San Mateo CA, US
Weijiang Zhang - Concord CA, US

Assignee:

Theravance, Inc. - South San Francisco CA

International Classification:

A61K 31/40
C07D 207/09

US Classification:

514428, 548571

Abstract:

The invention provides a crystalline naphthalene-1,5-disulfonic acid salt of 2-[(S)-1-(8-methylaminooctyl)pyrrolidin-3-yl]-2,2-diphenylacetamide or a solvate thereof. This invention also provides pharmaceutical compositions comprising the salt or prepared using the salt; processes and intermediates for preparing the salt; and methods of using the salt to treat a pulmonary disorder.

US Patent:

7728004, Jun 1, 2010

Filed:

Apr 5, 2006

Appl. No.:

11/398119

Inventors:

Paul R. Fatheree - San Francisco CA, US
S. Derek Turner - San Francisco CA, US
Adam A. Goldblum - San Francisco CA, US
Robert S. Chao - Santa Clara CA, US
Daniel Genov - San Francisco CA, US

Assignee:

Theravance, Inc. - South San Francisco CA

International Classification:

A61K 31/46
C07D 451/02

US Classification:

514304, 546126

Abstract:

The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3. 2. 1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HTreceptor activity, and processes useful for preparing such crystalline salt forms.

US Patent:

8304433, Nov 6, 2012

Filed:

Nov 13, 2009

Appl. No.:

12/617838

Inventors:

Lori Jean Patterson - San Francisco CA, US
Robert S. Chao - Santa Clara CA, US
Miroslav Rapta - Sunnyvale CA, US

Assignee:

Theravance, Inc. - South San Francisco CA

International Classification:

A61K 31/4409
C07D 211/22

US Classification:

514317, 546236

Abstract:

The invention provides a crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.

US Patent:

20050113413, May 26, 2005

Filed:

Oct 28, 2004

Appl. No.:

10/975657

Inventors:

Richard Wilson - El Sobrante CA, US
Julie Congdon - San Francisco CA, US
Mathai Mammen - Redwood Shores CA, US
Weijiang Zhang - Concord CA, US
Robert Chao - Santa Clara CA, US

International Classification:

A61K031/4545
C07D041/14

US Classification:

514316000, 546193000

Abstract:

This invention provides naphthalene-1,5-disulfonic acid salts of 4-{N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine, which salts are useful as muscarinic receptor antagonists. This invention is also directed to pharmaceutical compositions comprising these salt forms, methods of using these salt forms for treating medical conditions mediated by muscarinic receptors; and processes for preparing these salt forms.

US Patent:

20060183901, Aug 17, 2006

Filed:

Feb 16, 2006

Appl. No.:

11/355323

Inventors:

Paul Fatheree - San Francisco CA, US
S. Turner - San Francisco CA, US
Robert Chao - Santa Clara CA, US
Jyanwei Liu - Sunnyvale CA, US
Hao Zhang - Foster City CA, US
Daniel Genov - San Francisco CA, US
Junning Lee - El Granada CA, US

International Classification:

C07D 403/14

US Classification:

544363000

Abstract:

The invention provides crystalline halide salts of 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}amide and solvates thereof. The invention also provides pharmaceutical compositions comprising such salts, methods of using such crystalline salts to treat diseases associated with 5-HTreceptor activity, and processes useful for preparing such crystalline salts.

US Patent:

20080197913, Aug 21, 2008

Filed:

Feb 16, 2007

Appl. No.:

11/676121

Inventors:

Robert L. Chao - Los Altos CA, US

International Classification:

G05F 1/10

US Classification:

327541

Abstract:

A voltage detection circuit has a first MOSFET device having a drain, a gate, and a source terminal. A feedback element is coupled to the drain terminal and the gate terminal of the first MOSFET device. An input voltage is coupled to the gate terminal of the first MOSFET device. The voltage detection circuit is actively detecting a voltage from when the input voltage is in an OFF-state voltage region of the first MOSFET device. This detection continues through when the input voltage is at a sub-threshold voltage region of the first MOSFET, to when the input voltage exceeds the threshold voltage of the first MOSFET. This voltage detection circuit dissipates only a pre-selected drain-current at a level exceeding the drain-leakage current of the first MOSFET, as power dissipation.

US Patent:

20100197728, Aug 5, 2010

Filed:

Apr 13, 2010

Appl. No.:

12/759080

Inventors:

Paul R. Fatheree - San Francisco CA, US
S. Derek Turner - Reston VA, US
Adam A. Goldblum - Berkeley CA, US
Robert S. Chao - Santa Clara CA, US
Daniel Genov - Boston MA, US

Assignee:

THERAVANCE, INC. - South San Francisco CA

International Classification:

A61K 31/4709
C07D 215/20
A61P 43/00

US Classification:

514312, 546156

Abstract:

The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HTreceptor activity, and processes useful for preparing such crystalline salt forms.